Is nutritional status a new indicator to use in clinical practice for colorectal cancer patients?

doi:10.4251/wjgo.v16.i12.4537

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (146)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

HTML

Tables (1-2)

Sum=127

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=10

Dec 15, 2024 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4537-4542
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4537

Is nutritional status a new indicator to use in clinical practice for colorectal cancer patients?

Rossana Berardi, Rebecca Chiariotti, Giulia Mentrasti

Rossana Berardi, Rebecca Chiariotti, Giulia Mentrasti, Department of Medical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona 60126, Marche, Italy

Co-first authors: Rossana Berardi and Rebecca Chiariotti.

Author contributions: Berardi R, Chiariotti R, and Mentrasti G contributed to conception, design and manuscript writing.

Conflict-of-interest statement: Professor Rossana Berardi: Astra Zeneca, Advisory Board, Personal; Bayer, Advisory Board, Personal; Boehringer Ingelheim, Advisory Board, Personal; EISAI, Advisory Board, Personal; Incyte, Advisory Board, Personal; Lilly, Advisory Board, Personal; Menarini, Advisory Board, Personal; Merck, Advisory Board, Personal; MSD, Advisory Board, Personal; Gilead, Invited Speaker, Personal; Astra Zeneca, Funding, Institutional; Pfizer, Funding, Institutional; Roche, Funding, Institutional. The other authors indicated no financial relationships.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Rossana Berardi, MD, PhD, Professor, Department of Medical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, Ancona 60126, Marche, Italy. r.berardi@univpm.it

Received: April 30, 2024
Revised: June 20, 2024
Accepted: July 15, 2024
Published online: December 15, 2024
Processing time: 195 Days and 20.4 Hours

Core Tip

Core Tip: The controlling nutritional status (CONUT) score is significantly associated with the prognosis of colorectal cancer patients, as supported by a large body of literature. Compared with other nutritional scores, the CONUT score may be introduced in clinical practice as an optimal prognostic nutritional index to predict patient outcome.